2-Isobutyl-4-methyl-oxazol | 66577-43-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Isobutyl-4-methyl-oxazol
• 英文别名: 2-isobutyl-4-methyl-oxazole；4-Methyl-2-(2-methylpropyl)-1,3-oxazole
• CAS: 66577-43-3
• 化学式: C₈H₁₃NO
• 分子量: 139.197
• InChiKey: JPANOWOSDSMKTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES
  申请人：Bartolomé-Nebreda José Manuel

  公开号：US20120329792A1

  公开（公告）日：2012-12-27

  The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

  本发明涉及新型咪唑并[1,2-a]吡嗪衍生物，其为磷酸二酯酶10（PDE10）的抑制剂，并且适用于治疗或预防涉及PDE10酶的神经、精神和代谢性疾病。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物或药物组合物预防或治疗神经、精神和代谢性疾病和疾病。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Corkey Britton Kenneth

  公开号：US20120289493A1

  公开（公告）日：2012-11-15

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R 1 , X 1 , X 2 , Y and R 2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类为钠通道抑制剂的化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，该化合物的结构由式I给出： 其中Q、R1、X1、X2、Y和R2如本文所述，以及制备和使用该化合物的方法，以及含有该化合物的药物组合物。
• [EN] INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE LA GLYCOGÈNE SYNTHASE 1 (GYS1) ET LEURS MÉTHODES D'UTILISATION
  申请人：MAZE THERAPEUTICS INC

  公开号：WO2022198196A1

  公开（公告）日：2022-09-22

  Provided herein are compounds of formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y2, Y3, L1, L2, X1, X2, X3, X4, X5, Q1, R1, R2, Rk, Rm, and Rnare as defined elsewhere herein. Also provided herein are methods of preparing compounds of formula (F). Also provided herein are methods of inhibiting GYS1 and methods of treating a GYS1 -mediated disease, disorder, or condition in an individual in need thereof.

  本文提供了公式(I')的化合物或其立体异构体或互变异构体，或任何其药学上可接受的盐，其中Y2，Y3，L1，L2，X1，X2，X3，X4，X5，Q1，R1，R2，Rk，Rm和Rn的定义在本文其他部分中已经说明。本文还提供了制备公式(F)化合物的方法。本文还提供了抑制GYS1的方法以及治疗需要该方法的个体中的GYS1介导的疾病，障碍或状况的方法。
• Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
  申请人：Array BioPharma, Inc.

  公开号：US10953005B1

  公开（公告）日：2021-03-23

  Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供的是式 I 的化合物： 及其立体异构体和药学上可接受的盐或溶液，其中 A、B、X1、X2、X3、X4、环 D 和 E 具有说明书中给出的含义，它们是 RET 激酶的抑制剂，可用于治疗和预防可以用 RET 激酶抑制剂治疗的疾病，包括 RET 相关疾病和紊乱。
• EP2545055B1
  申请人：——

  公开号：EP2545055B1

  公开（公告）日：2017-08-09